# Study to Assess the Effect of Renal Impairment on the Pharmacokinetics of CTP-543

> **NCT05468749** · PHASE1 · COMPLETED · sponsor: **Concert Pharmaceuticals** · enrollment: 16 (actual)

## Conditions studied

- Renal Impairment

## Interventions

- **DRUG:** CTP-543

## Key facts

- **NCT ID:** NCT05468749
- **Lead sponsor:** Concert Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-06-06
- **Primary completion:** 2022-10-20
- **Final completion:** 2022-10-27
- **Target enrollment:** 16 (ACTUAL)
- **Last updated:** 2022-11-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05468749

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05468749, "Study to Assess the Effect of Renal Impairment on the Pharmacokinetics of CTP-543". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT05468749. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*